Drug intelligence / Profile preview

Bergastatil

Development stage
Unknown
Lead developer
Aflofarm
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Bergastatil is an oral dietary supplement developed and marketed by the Polish pharmaceutical company Aflofarm. It is formulated as hard capsules containing a combination of two primary botanical extracts: bergamot fruit extract (*Citrus bergamia*), standardized to 60% polyphenols, and garlic extract, standardized to contain allicin. The product is intended to support the maintenance of healthy blood cholesterol levels and overall cardiovascular health. The polyphenolic flavonoids in the bergamot extract are purported to reduce LDL cholesterol and triglycerides while supporting HDL levels, potentially through the inhibition of HMG-CoA reductase, while the garlic component contributes to vascular health and cholesterol management. Bergastatil is marketed in Poland for adult use and is contraindicated for individuals taking statins or other lipid-lowering medications.

Brand names
Bergastatil
Other names
bergamot extract
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on Bergastatil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bergastatil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call